A Comprehensive Approach to Managing HER2-Positive Breast Cancer


A Comprehensive Approach to Managing HER2-Positive Breast Cancer

Topic: Oncology
Relevant Terms: Breast cancer, HER2+, immunohistochemistry, in-situ hybridization, targeted treatment, shared decision-making
Primary Audience: Oncologists, nurse practitioners, nurses, physician assistants, and other clinicians who specialize in oncology and management of patients with breast cancer
Launch Date: 03-Oct-17
Credits: AMA PRA Category 1 Credit
Expiration Date: 03-Oct-18
Curriculum Name: A Comprehensive Approach to Managing HER2-Positive Breast Cancer

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Utilize the updated ASCO/CAP 2013 guidelines and the most recent NCCN guidelines for breast cancer to improve detection and classification of HER2 status
  2. Apply current efficacy and safety data to select targeted treatments that improve outcomes for patients with HER2-positive breast cancer
  3. Apply current guideline-recommended neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
  4. Effectively engage patients with HER2-positive breast cancer in their healthcare by implementing effective shared decision-making strategies


    Ruth M. O'Regan, MD
    Chief, Division of Hematology/Oncology and Palliative Care
    Endowed Professor of Hematology/Oncology
    Department of Medicine
    University of Wisconsin School of Medicine and Public Health
    Madison, WI
    Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP
    Nurse Practitioner, McKelvey Lung Transplant Center
    Emory University Hospital
    Adjunct Faculty, Nell Hodgson Woodruff School of Nursing
    Emory University
    Atlanta, GA
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Ruth O'Regan, MD, has affiliations with Lilly (Consulting); and Oncothyreon (Contracted Research).
    • Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP, has no affiliations with commercial interest to disclose.
    RMEI Medical Education, LLC
    • Elizabeth Paczolt, MD, has no affiliations with commercial interests to disclose.
    Postgraduate Institute for Medicine 
    Planners and Managers
    The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Estimated time to complete: 1 hour
    Media: Internet
    There is no fee for this educational activity.
    This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent educational grant from Genentech.  
    By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.